Who We Are
The Sickle Cell Disease Partnership is a multi-sector collaboration of health care stakeholders committed to advancing actionable federal health care policies that will improve the lives of patients living with Sickle Cell Disease.
The Sickle Cell Disease Partnership’s work is rooted in the 2020 report from The National Academies of Science, Engineering, and Medicine’s (National Academies), “Addressing Sickle Cell Disease: A Strategic Plan and Blueprint for Action.” The Partnership’s main objective is to work collaboratively across the Sickle Cell Disease community to translate the recommendations of the National Academies’ foundational report into legislative and administrative actions in Congress and the Executive Branch.
Cheryl De Pinto, MD, MPH, FAAP
Senior Vice President, Primary Care and Subspecialty Pediatrics
Martha L. Liggett, Esq.
The Partnership is composed of Sickle Cell Disease patient and community organizations, health care providers who have experience caring for Sickle Cell patients, manufacturers of medical products, health plans, researchers, and others interested in improving the lives of patients living with Sickle Cell Disease.
National Academy of Medicine (Observer)
Access to New Therapies
Committed to achieving policy objectives that promote timely, quality and equitable access to treatments and therapies.
Care Delivery and Access
Dedicated to ensuring timely, sustained access to high-quality, equitable, coordinated and comprehensive primary, subspecialty and psychosocial care.
Data and Evidence
Focused on achieving policy objectives that break down existing barriers and promote the collection and standardization of reliable, high-utility data on those living with Sickle Cell.